Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H3N2v LAIV in Healthy Children and Adults
NCT02883426Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2016
- Primary completion
- Jan 2017
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of H3N2v MN 2010/AA ca live attenuated influenza vaccine in influenza (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of vaccine-related reactogenicity events at Day 180, Area under the curve of nasal virus shedding at Day 180 and 1 more. Started Sep 2016; status: terminated.
02
Drugs
H3N2v MN 2010/AA ca live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02883426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883426.